PMID- 28497487
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20220408
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 46
IP  - 2
DP  - 2017 Jul
TI  - Systematic review with meta-analysis: the efficacy of vonoprazan-based triple 
      therapy on Helicobacter pylori eradication.
PG  - 106-114
LID - 10.1111/apt.14130 [doi]
AB  - BACKGROUND: In order to increase eradication rates, vonoprazan, a novel 
      potassium-competitive acid blocker, has been used in Helicobacter pylori 
      eradication therapy. AIM: To summarise the results of the efficacy of 
      vonoprazan-based triple therapy, helping clinicians to better understand the 
      benefit of vonoprazan in the treatment of H. pylori infection. METHODS: We 
      conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane 
      Library using the primary keywords "vonoprazan," "takecab", "TAK-438," 
      "potassium," "competitive," "potassium-competitive," "Helicobacter," and 
      "pylori." Studies were included if they evaluated the eradication rate between 
      the vonoprazan-based and proton pump inhibitor (PPI)-based triple therapies. 
      RESULTS: Ten studies and 10 644 patients were evaluated. The crude H. pylori 
      eradication rate determined by intention-to-treat analysis was 87.9% and 72.8% in 
      the vonoprazan-based triple therapy and PPI-based triple therapy respectively. 
      The eradication rate of the vonoprazan-based triple therapy was superior to that 
      of the PPI-based triple therapy (pooled risk ratio [RR] [95% confidence interval 
      (CI)]=1.19 [1.15-1.24]) In addition, there was no significant difference in 
      dropout rate due to adverse event between the regimens (pooled RR of the 
      vonoprazan-based triple therapy [95% CI]=0.69 [0.23-2.03]). The incidence of any 
      adverse events also did not differ between the regimens (pooled RR [95% CI]=1.02 
      [0.78-1.34]). CONCLUSIONS: The vonoprazan-based triple therapy showed superior 
      efficacy in terms of H. pylori eradication as compared to the PPI-based triple 
      therapy. In addition, the vonoprazan-based triple therapy showed comparable 
      tolerability and incidence of adverse events.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Jung, Y S
AU  - Jung YS
AD  - Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung 
      Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Kim, E H
AU  - Kim EH
AD  - Division of Gastroenterology, Department of Internal Medicine, Severance 
      Hospital, Yonsei University College of Medicine, Seoul, Korea.
FAU - Park, C H
AU  - Park CH
AUID- ORCID: 0000-0003-3824-3481
AD  - Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang 
      University College of Medicine, Guri, Korea.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20170512
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 
      (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Pyrroles)
RN  - 0 (Sulfonamides)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
CIN - Aliment Pharmacol Ther. 2017 Sep;46(5):551-552. PMID: 28776746
CIN - Aliment Pharmacol Ther. 2017 Sep;46(5):550-551. PMID: 28776748
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Clarithromycin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori
MH  - Humans
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Pyrroles/*therapeutic use
MH  - Sulfonamides/*therapeutic use
EDAT- 2017/05/13 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/05/13 06:00
PHST- 2017/02/09 00:00 [received]
PHST- 2017/03/05 00:00 [revised]
PHST- 2017/04/13 00:00 [accepted]
PHST- 2017/05/13 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/05/13 06:00 [entrez]
AID - 10.1111/apt.14130 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2017 Jul;46(2):106-114. doi: 10.1111/apt.14130. Epub 2017 
      May 12.